期刊文献+

STAT3和SOCS3蛋白在中耳胆脂瘤中的表达及意义 被引量:3

The Expression of STAT3 and SOCS3 Protein in the Middle Ear Cholesteatoma
下载PDF
导出
摘要 目的研究信号转导和转录激活因子3(signal transducer and activator of transcription 3,STAT3)和细胞因子信号抑制因子3(suppressor of cytokine signaling 3,SOCS3)在中耳胆脂瘤中的表达及意义。方法采用免疫组织化学法检测30例中耳胆脂瘤标本与20例正常外耳道皮肤中STAT3及SOCS3蛋白的表达。结果STAT3蛋白阳性表达定位于胞浆和胞核,其在中耳胆脂瘤上皮中阳性表达率为76.7%(23/30),高于正常外耳道皮肤组的25.0%(5/20),差异有统计学意义(P<0.05);SOCS3蛋白阳性表达主要定位于胞浆,其在中耳胆脂瘤上皮的阳性表达率为33.3%(10/30),低于正常外耳道皮肤组的65.0%(13/20),差异有统计学意义(P<0.05);在30例中耳胆脂瘤上皮组织中,STAT3与SOCS3蛋白的表达呈负相关(r=-0.476,P=0.008,P<0.05)。结论STAT3和SOCS3蛋白在中耳胆脂瘤中的异常表达可能与中耳胆脂瘤上皮细胞的过度增殖和凋亡抑制相关,进而参与了胆脂瘤的发生发展。 Objective To study the expression of signal transducer and activator of transcription 3 (STAT3) and Suppressor of cytokine signaling 3(SOCS3) in the middle ear cholesteatoma epithelium ,and the possible roles of STAT3 and SOCS3 in middle ear cholesteatoma. Methods The immunohistochemical assay was used to detect expression of STAT3 and SOCS3 protein in 30 cases of middle ear cholesteatoma epithelial tissue and 20 cases of normal external auditory canal skin tissues as the control group. Results STAT3 immunoreactivity was detected in the nuclei and cytoplasm of epithelial cells. The expression rates of STAT3 in middle ear cholesteatoma epithelial tissue were 76.7% and higher than in the normal epithelium (25.0%). The differences between the two groups were statistically significant (P%0.05). SOCS3 immunoreactivity was detected in the cytoplasm of epithelial cells. The expression rates of SOCS3 in middle ear cholesteatoma epithelial tissue were 33.3 % and lower than in the normal epithelium (65.0 % ). The differences were statistically significant (P〈0.05). The expression of STAT3 and SOCS3 in the middle ear eholesteatoma had negative correlation (r = -- 0. 476, P〈0.05). Conclusion The abnormal expression of STAT3 and SOCS3 in the middle ear cholesteatoma may be involved in hyper proliferation and anti--apoptosis of eholesteatoma cell, and play an important role in the formation and development of middle ear cholesteatoma.
出处 《听力学及言语疾病杂志》 CAS CSCD 北大核心 2016年第3期265-268,共4页 Journal of Audiology and Speech Pathology
关键词 信号转导和转录激活因子3 细胞因子信号抑制因子3 胆脂瘤 中耳 Signal transducer and activator of transcription 3(STAT3) Suppressor of cytokine signaling 3 (SOCS3) Cholesteatoma Middle ear
  • 相关文献

参考文献13

  • 1Tamiya T,Kashiwagi I,Takahashi R,et al.Suppressors of cytokine signaling(SOCS)proteins and JAK/STAT pathways:regulation of T-cell inflammation by SOCS1 and SOCS3[J].Arterioscler Thromb Vasc Biol,2011,31:980.
  • 2Martha LS,Abbie L,Lisa MH,et al.Genetic variation in the JAK/STAT/SOCS signaling pathway influences breast cancer-specific mortality through interaction with cigarette smoking and use of aspirin/NSAIDs:The breast cancer health disparities study[J].Breast Cancer Res Treat,2014,147:145.
  • 3潘松林,龚树生.中耳胆脂瘤发病机制研究进展[J].听力学及言语疾病杂志,2008,16(4):338-340. 被引量:4
  • 4杨宁,蒋立新.凋亡抑制蛋白Livin及Survivin在中耳胆脂瘤上皮的表达及意义[J].听力学及言语疾病杂志,2011,19(4):356-358. 被引量:5
  • 5Park HR,Min SK,Min K,et al.Increased expression of p63and survivin in cholesteatomas[J].Acta Otolaryngol,2009,129:268.
  • 6Teramo A,Gattazzo C,Passeri F,et al.Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia[J].Blood,2013,121:3843.
  • 7Kiu H,Nicholson SE.Biology and significance of the JAK/STAT signalling pathways[J].Growth Factors,2012,30:88.
  • 8Friedland DR,Eernisse R,Erbe C,et al.Cholesteatoma growth and proliferation:posttranscriptional regulation by microRNA-21[J].Otol Neurotol,2009,30:998.
  • 9Croker BA,Kiu H,Nicholson SE.SOCS regulation of the JAK/STAT signaling pathway[J].Semin Cell Dev Biol,2008,19:414.
  • 10Krebs DL,Hilton DJ.SOCS proteins:negative regulators of cytokine signaling[J].Stem Cells,2001,19:378.

二级参考文献40

  • 1Ergun S, Carlsoo B, Zheng X esteatoma and Squamous cell Otolaryngol, 1999,24 : 280.
  • 2Apoptosis in meatal skin,chob carcinoma of the ear[J]. Clin Sasaki H, Huang CC. Expression of cytokeratins 13 and 16 in middle ear cholesteatoma [J]. Otolaryngol Head Neck Surg, 1994,110:310.
  • 3Bujia J, Sudhoff H, Holly A, et al. Immunohistochemical de tection of proliferating cell nuclear antigen in middle ear chol esteatoma[J]. Eur Arch Otorhinolaryngol, 1996,253 : 21.
  • 4Park HJ, Park K. Expression of Fas/APO 1 and apoptosis of keratinocytesin human cholesteatoma[J]. Laryngoscope, 1999, 109:613.
  • 5Kojima H, Tanaka Y, Tanaka T, et al. Cell proliferation and apoptosis in human middle ear cholesteatoma[J]. Archives of Otolaryngology- Head'Neck Surgery, 1998,124 : 261.
  • 6Shinoda H, Huang CC. Expressions of c-jun and P53 pro teins in human middle ear cholesteatoma:Relationship to kera tioncyte proliferation differatiation and programmed cell death [J]. Laryngoscope, 1995,105:1 232.
  • 7Kosa R, Yagi M, Tabe H, et al. Kinetic analysis of cell pro liferation using bromodeoxyuridine labeling and in situdetection of dying cells in the tympanic membrane and middle ear eholeateatoma[J]. Arch Histol Cytol, 1996,59 : 339.
  • 8Vucic D, Stennicke HR, Pisabarro MT,et al. ML-IAP,a no vel inhibitor of apoptosis that is preferentially expressed in hu man melanomas[J]. Curr Biol, 2000,10 : 1 359.
  • 9Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member[J]. J Biol Chem, 2001,276 : 3 238.
  • 10Yagihashi A, Asanuma K, Tsuii N, et al. Detection of an tiLivin antibody in gastrointestinal cancer patiences[J]. Clin Chem,2003,49 : 1 206.

共引文献7

同被引文献22

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部